Obesity

Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.

In the U.S., diabetic ketoacidosis frequency at prenatal and delivery hospitalizations increased from 2010 to 2020 for mothers with pregestational diabetes, according to study results published in Obstetrics & Gynecology.

Tirzepatide significantly reduced HF outcomes and symptoms for patients with HF and preserved ejection fraction and obesity, according to the top-line results of the phase 3 SUMMIT clinical trial.

Individuals with type 2 diabetes who received semaglutide had lower probability for medical care related to tobacco dependence compared with other antidiabetes medications, the results of a study in the Annals of Internal Medicine showed.

Optometry in the 21st century has moved strongly toward evidence-based medicine, with the American Optometric Association even publishing a 14-step process to assist in the development of an evidence-based practice.

The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release.

Early initiation of a school-based health education intervention limited adiposity marker progression in elementary-aged children in Spain, researchers reported.

A cross-sectional study revealed that increased vitamin A intake may improve depressive symptoms in patients with heart failure.

Obesity accounts for much of the risk for primary hypertension, and a treatment plan that could address both issues could substantially reduce a person’s underlying risk for cardiovascular disease and other complications.

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.